United Capital Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-3,995
| Closed | -$263K | – | 1060 |
|
|
2024
Q4 | $263K | Buy |
+3,995
| New | +$263K | ﹤0.01% | 922 |
|
|
2024
Q3 | – | Sell |
-4,742
| Closed | -$390K | – | 1059 |
|
|
2024
Q2 | $390K | Sell |
4,742
-1,408
| -23% | -$116K | ﹤0.01% | 771 |
|
|
2024
Q1 | $537K | Buy |
6,150
+3,250
| +112% | +$284K | ﹤0.01% | 716 |
|
|
2023
Q4 | $280K | Buy |
2,900
+216
| +8% | +$20.8K | ﹤0.01% | 894 |
|
|
2023
Q3 | $237K | Buy |
2,684
+28
| +1% | +$2.48K | ﹤0.01% | 767 |
|
|
2023
Q2 | $230K | Sell |
2,656
-303
| -10% | -$26.3K | ﹤0.01% | 824 |
|
|
2023
Q1 | $288K | Sell |
2,959
-2,026
| -41% | -$197K | ﹤0.01% | 833 |
|
|
2022
Q4 | $516K | Sell |
4,985
-9,208
| -65% | -$953K | ﹤0.01% | 748 |
|
|
2022
Q3 | $1.2M | Sell |
14,193
-42
| -0.3% | -$3.56K | 0.01% | 576 |
|
|
2022
Q2 | $1.18M | Sell |
14,235
-375
| -3% | -$31.1K | 0.01% | 604 |
|
|
2022
Q1 | $1.13M | Sell |
14,610
-240
| -2% | -$18.5K | 0.01% | 635 |
|
|
2021
Q4 | $1.31M | Sell |
14,850
-420
| -3% | -$37.1K | 0.01% | 623 |
|
|
2021
Q3 | $1.18M | Buy |
15,270
+95
| +0.6% | +$7.34K | 0.01% | 631 |
|
|
2021
Q2 | $1.27M | Sell |
15,175
-8,483
| -36% | -$708K | 0.01% | 637 |
|
|
2021
Q1 | $1.79M | Buy |
23,658
+14,391
| +155% | +$1.09M | 0.01% | 528 |
|
|
2020
Q4 | $813K | Sell |
9,267
-8,899
| -49% | -$781K | ﹤0.01% | 727 |
|
|
2020
Q3 | $1.38M | Buy |
18,166
+12,733
| +234% | +$969K | 0.01% | 582 |
|
|
2020
Q2 | $670K | Buy |
5,433
+240
| +5% | +$29.6K | ﹤0.01% | 762 |
|
|
2020
Q1 | $439K | Buy |
5,193
+1,447
| +39% | +$122K | ﹤0.01% | 854 |
|
|
2019
Q4 | $317K | Buy |
+3,746
| New | +$317K | ﹤0.01% | 1111 |
|